Genentech wins Chiron patent case
Executive Summary
A Chiron patent claiming monoclonal antibodies that bind selectively to the HER-2 antigen is invalid, a federal appeals court ruled March 30. Chiron sued Genentech in 2000, claiming the firm's oncologic Herceptin (trastuzumab) infringed the Chiron patent. The Federal Circuit 1ruling affirms a Sacramento, Calif. court's judgment in favor of Genentech (2"The Pink Sheet" Sept. 16, 2002, In Brief)...
You may also be interested in...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.